Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Anal Cancer Metastatic 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × reolysin × 1 year × Clear all
NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting
122 enrolled
Gastrointestinal

Anal Cancer Metastatic

NCT05514990 2026-05-13

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

University of Southern California

Phase 1/2 Active not recruiting
10 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡